Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside for Arterial Stiffness and Elevated SBP in CKD
NCT04040959Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Nov 2019
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nicotinamide riboside in chronic kidney disease (CKD), arterial stiffness, hypertension (HTN), sponsored by University of Colorado Denver. Started Nov 2019; status: active, not recruiting.
02
Drugs
nicotinamide riboside
03
Conditions
chronic kidney disease (CKD)arterial stiffnesshypertension (HTN)
Beyond the preview
Go deeper on NCT04040959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040959.